nach oben

Clinical Rheumatology

Erschienen in:

26.05.2018 | Review Article

Advances in the diagnosis and treatment of Sjogren’s syndrome

verfasst von: Xiaoyun Chen, Huaxun Wu, Wei Wei

Erschienen in: Clinical Rheumatology | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Sjogren’s syndrome (SS) is a systemic autoimmune disease that primarily affects the exocrine glands, resulting in dryness of the eyes and mouth due to lymphocytic infiltration of the salivary and lacrimal glands along with arthritis, kidney, liver, and lung involvement, chronic fatigue, musculoskeletal pain, vasculitis, and so on. Considerable advance has been made for the classification and treatment of primary SS in the past few years. This article reviews the recent classification criteria for primary SS and briefly discusses the conventional and novel therapies of the disease.

Ferro F, Marcucci E, Orlandi M, Baldini C, Bartoloni-Bocci E (2017) One year in review 2017: primary Sjogren’s syndrome. Clin Exp Rheumatol 35:179–191PubMed

Patel R, Shahane A (2014) The epidemiology of Sjögren’s syndrome. Clin Epidemiol 6:247–255PubMedPubMedCentral

Mavragani CP (2017) Mechanisms and new strategies for Sjögren’s syndrome. Annu Rev Med 68:331–343CrossRefPubMed

Both T, Dalm VA, van Hagen PM, van Daele PL (2017) Reviewing primary Sjögren’s syndrome: beyond the dryness—from pathophysiology to diagnosis and treatment. Int J Med Sci 14:191–200CrossRefPubMedPubMedCentral

Verstappen GM, Meiners PM, Corneth OBJ, Visser A, Arends S, Abdulahad WH, Hendriks RW, Vissink A, Kroese FGM, Bootsma H (2017) Abatacept attenuates T follicular helper-cell-dependent B-cell hyperactivity in primary Sjögren’s syndrome. Arthritis Rheumatol 69:1850–1861CrossRefPubMed

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren's Syndrome (2002) Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558CrossRefPubMedPubMedCentral

Gonzales JA, Lietman TM (2018) Ocular involvement in Sjögren’s syndrome: advances in therapy. Curr Treatm Opt Rheumatol 4:99–109CrossRef

Nair JJ, Singh TP (2017) Sjogren’s syndrome: review of the aetiology, pathophysiology & potential therapeutic interventions. J Clin Exp Dent 9:584–589

Lojacono A, Nascimbeni G, Favero M et al (2013) Novel aspects of Sjogren’s syndrome in 2012. BMC Med 11:93–110CrossRefPubMedPubMedCentral

10.

Shiboski SC, Shiboski CH, Criswell L et al (2012) American College of Rheumatology Classification Criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the SICCA cohort. Arthritis Care Res 64:475–487CrossRef

11.

Sankar V, Noll JL, Brennan MT (2014) Diagnosis of Sjögren’s syndrome: American-European and the American College of Rheumatology Classification Criteria. Atlas Oral Maxillofac Surg Clin North Am 26:13–22CrossRef

12.

Chu CS, Chi CM (2017) Diagnosis and treatment of primary Sjogren’s syndrome: an update. HK Bull Rheum Dis 17:6–11

13.

Huo AP, Lin KC, Chou CT (2010) Predictive and prognostic value of antinuclear antibodies and rheumatoid factor in primary Sjögren’s syndrome. Int J Rheum Dis 13:39–47CrossRefPubMed

14.

Rasmussen A, Ice JA, Li H, Grundahl K, Kelly JA, Radfar L, Stone DU, Hefner KS, Anaya JM, Rohrer M, Gopalakrishnan R, Houston GD, Lewis DM, Chodosh J, Harley JB, Hughes P, Maier-Moore JS, Montgomery CG, Rhodus NL, Farris AD, Segal BM, Jonsson R, Lessard CJ, Scofield RH, Sivils KLM (2014) Comparison of the American-European Consensus Group Sjögren’s syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterized sicca cohort. Ann Rheum Dis 73:31–47CrossRefPubMed

15.

Franceschini F, Cavazzana I, Andreoli L, Tincani A (2017) The 2016 classification criteria for primary Sjogren’s syndrome: what’s new. BMC Med 15:69–71CrossRefPubMedPubMedCentral

16.

Baer AN, Mcadams DeMarco M, Shiboski SC et al (2015) The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjogren’s syndrome. Ann Rheum Dis 74:1557–1561CrossRefPubMed

17.

Billings M, Amin Hadavand M (2018) Comparative analysis of the 2016 ACR-EULAR and the 2002 AECG classification criteria for Sjögren’s syndrome: findings from the B GNIH cohort. Oral Dis 24:184–190CrossRefPubMed

18.

Vitali C, Del PN (2017) Classification and diagnostic criteria in Sjogren’s syndrome: a long-standing and still open controversy. Ann Rheum Dis 76:1953–1954CrossRefPubMed

19.

Kuklinski E, Asbell PA (2017) Sjogren’s syndrome from the perspective of ophthalmology. Clin Immunol 182:55–61CrossRefPubMed

20.

Wang K, Shi L, Yu Z, Deng Z, He A, Li S, Liu L (2015) Cyclosporine A suppresses the activation of the Th17 cells in patients with primary Sjogren’s syndrome. Iran J Allergy Asthma Immunol 14:198–207PubMed

21.

Kawakita T, Shimmura S, Tsubota K (2015) Effect of oral pilocarpine in treating severe dry eye in patients with Sjogren syndrome. Asia Pac J Ophthalmol (Phila) 4:101–105CrossRef

22.

Shih KC, Lun CN, Jhanji V, Thong YH, Tong L (2017) Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome. J Inflamm 14:26–37CrossRef

23.

Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P (2002) A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheumatol 46:748–754CrossRef

24.

Ono M, Takamura E, Shinozaki K, Tsumura T, Hamano T, Yagi Y, Tsubota K (2004) Therapeutic effect of cevimeline on dry eye in patients with Sjogren’s syndrome: a randomized, double-blind clinical study. Am J Ophthalmol 138:6–17CrossRefPubMed

25.

Demarchi J, Papasidero S, Medina MA, Klajn D, Chaparro del Moral R, Rillo O, Martiré V, Crespo G, Secco A, Catalan Pellet A, Amitrano C, Crow C, Asnal C, Pucci P, Caeiro F, Benzanquen N, Pirola JP, Mayer M, Zazzetti F, Velez S, Barreira J, Tamborenea N, Santiago L, Raiti L (2017) Primary Sjögren’s syndrome: extraglandular manifestations and hydroxychloroquine therapy. Clin Rheumatol 36:2455–2460CrossRefPubMed

26.

Papa ND, Vitali C (2018) Management of primary Sjögren’s syndrome: recent developments and new classification criteria. Ther Adv Musculoskelet Dis 10:39–54CrossRefPubMedPubMedCentral

27.

Wang SQ, Zhang LW, Wei P, Hua H (2017) Is hydroxychloroquine effective in treating primary Sjogren’s syndrome: a systematic review and meta-analysis. BMC Musculoskelet Disord 18:186–199CrossRefPubMedPubMedCentral

28.

Kedor C, Zernicke J, Hagemann A, Gamboa LM, Callhoff J, Burmester GR, Feist E (2016) A phase II investigator initiated pilot study with low dose cyclosporine A for the treatment of articular involvement in primary Sjogren’s syndrome. Clin Rheumatol 35:2203–2210CrossRefPubMed

29.

Cornec D, Jamin C, Pers O (2014) Sjogren’s syndrome: where do we stand, and where shall we go? J Autoimmun 51:109–114CrossRefPubMed

30.

Saraux A, Pers JO, Devauchelle-Pensec V (2016) Treatment of primary Sjogren syndrome. Nat Rev Rheumatol 12:456–471CrossRefPubMed

31.

Bowman SJ, Everett CC, O'Dwyer JL et al (2017) Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren’s syndrome. Arthritis Rheumatol 43:1440–1450CrossRef

32.

Mekinian A, Ravaud P, Hatron PY, Larroche C, Leone J, Gombert B (2012) Efficacy of rituximab in primary Sjogren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 71:84–87CrossRefPubMed

33.

Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, le Guern V, Aouba A, Sibilia J, Gottenberg JE, Mariette X (2007) Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Ann Rheum Dis 66:351–357CrossRefPubMed

34.

Mariette X, Le RS, Quartuccio L et al (2015) Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 74:526–531CrossRefPubMed

35.

Quartuccio L, Salvin S, Corazza L, Gandolfo S, Fabris M, De VS (2016) Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren’s syndrome: follow-up after the end of the phase II open-label BELISS study. Clin Exp Rheumatol 34:311–314PubMed

36.

Mavragani CP (2017) Mechanisms and new strategies for primary Sjögren’s syndrome. Annu Rev Med 68:331–343CrossRefPubMed

37.

Sieger N, Fleischer SJ, Mei HE, Reiter K, Shock A, Burmester GR, Daridon C, Dörner T (2013) CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+), flux upon activation. Arthritis Rheum 65:770–779CrossRefPubMed

38.

Steinfeld SD, Tant L, Burmester GR, Teoh NKW, Wegener WA, Goldenberg DM, Pradier O (2006) Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren’s syndrome: an open-label phase I/II study. Arthritis Res Ther 8:R129CrossRefPubMedPubMedCentral

39.

Tsuboi H, Matsumoto I, Hagiwara S, Hirota T, Takahashi H, Ebe H, Yokosawa M, Hagiya C, Asashima H, Takai C, Miki H, Umeda N, Kondo Y, Ogishima H, Suzuki T, Hirata S, Saito K, Tanaka Y, Horai Y, Nakamura H, Kawakami A, Sumida T (2015) Efficacy and safety of abatacept for patients with Sjögren’s syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren’s syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study. Interim ana. Mod Rheumatol 25:187–193CrossRefPubMed

40.

Nocturne G, Cornec D, Seror R, Mariette X (2016) Use of biologics in Sjögren’s syndrome. Rheum Dis Clin N Am 42:407–417CrossRef

41.

Mariette X, Ravaud P, Steinfeld S et al (2014) Inefficacy of infliximab in primary Sjögren’s syndrome: results of the randomized, controlled trial of remicade in primary Sjögren’s syndrome (TRIPSS). Arthritis Rheumatol 50:1270CrossRef

42.

Türkoğlu EB, Tuna S, Alan S et al (2015) Effect of systemic infliximab therapy in patients with Sjögren’s syndrome/Sekonder Sjogren sendromlu hastalarda sistemik infliksimab tedavisinin etkinligi. Turk J Ophthalmol 45:138–141CrossRef

43.

Nakahara H, Kawamoto K, Mori H et al (2014) AB0485 tocilizumab is effective for the patient with Sjogren’s syndrome complicated with rheumatoid arthritis. Ann Rheum Dis 73:967–968

44.

Marino A, Narula S, Lerman M (2017) First pediatric patient with Neuromyelitis optica and Sjogren’s syndrome successfully treated with tocilizumab. Pediatr Neurol 73:5–6CrossRef

45.

Wei W (2016) Soft regulation of inflammatory immune response. CPB 32:297–303

Titel: Advances in the diagnosis and treatment of Sjogren’s syndrome
verfasst von: Xiaoyun Chen
Huaxun Wu
Wei Wei
Publikationsdatum: 26.05.2018
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 7/2018
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-018-4153-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Advances in the diagnosis and treatment of Sjogren’s syndrome

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2018

Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis

Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with clinical and laboratory parameters of disease activity

The outcomes and risk factors of early readmission in patients with intestinal Behçet’s disease

Correction to: Intramuscular clodronate in erosive osteoarthritis of the hand is effective on pain and reduces serum COMP: a randomized pilot trial–The ER.O.D.E. study (ERosive Osteoarthritis and Disodium-clodronate Evaluation)

Pain threshold and temporomandibular function in systemic sclerosis: comparison with psoriatic arthritis

Brief communication: use of the minimal important difference for a meta-analysis on exercise and anxiety in adults with arthritis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin